Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat plus regional citrate anticoagulation versus regional citrate anticoagulation alone during CRRT in critically ill COVID-19 patients
ChiCTR2300067943Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Nafabelltan and trisodium citrate in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Life of extracorporeal circulation line, All-cause mortality at 14 days and 2 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Nafabelltantrisodium citrate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300067943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067943.